×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CAPR – capricor therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CAPR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/20
10:48 am
capr
Capricor wins key EU designations for the lead asset [Seeking Alpha]
Low
Report
Capricor wins key EU designations for the lead asset [Seeking Alpha]
11/20
10:22 am
capr
Parent Project Muscular Dystrophy Culminates 30th Anniversary with Celebratory "Investing in Every Future" Event [Yahoo! Finance]
Low
Report
Parent Project Muscular Dystrophy Culminates 30th Anniversary with Celebratory "Investing in Every Future" Event [Yahoo! Finance]
11/20
09:08 am
capr
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency [Yahoo! Finance]
Low
Report
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency [Yahoo! Finance]
11/20
09:00 am
capr
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
Low
Report
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
11/15
06:32 am
capr
Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]
Low
Report
Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]
11/14
01:34 pm
capr
Capricor Therapeutics Inc (NASDAQ: CAPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $77.00 price target on the stock.
Medium
Report
Capricor Therapeutics Inc (NASDAQ: CAPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $77.00 price target on the stock.
11/14
09:06 am
capr
Capricor Therapeutics Inc (NASDAQ: CAPR) had its price target raised by analysts at Cantor Fitzgerald from $25.00 to $30.00. They now have an "overweight" rating on the stock.
Medium
Report
Capricor Therapeutics Inc (NASDAQ: CAPR) had its price target raised by analysts at Cantor Fitzgerald from $25.00 to $30.00. They now have an "overweight" rating on the stock.
11/13
04:01 pm
capr
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Date
Time
Symbol
Company Name
Action
%Chg
11/13/2024
04:01 pm
capr
capricor therapeutics, inc.
MISS
Report
10.7%
capricor therapeutics, inc.
8/7/2024
04:05 pm
capr
capricor therapeutics, inc.
MISS
Report
9.0%
capricor therapeutics, inc.
5/13/2024
04:05 pm
capr
capricor therapeutics, inc.
MISS
Report
-6.3%
capricor therapeutics, inc.
2/29/2024
04:05 pm
capr
capricor therapeutics, inc.
BEAT
Report
8.7%
capricor therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
04:31 pm
capr
Form 10-Q CAPRICOR THERAPEUTICS, For: Sep 30
Low
Report
Form 10-Q CAPRICOR THERAPEUTICS, For: Sep 30
11/13
04:03 pm
capr
Form 8-K CAPRICOR THERAPEUTICS, For: Nov 13
Medium
Report
Form 8-K CAPRICOR THERAPEUTICS, For: Nov 13
11/12
11:47 am
capr
Form SC 13G CAPRICOR THERAPEUTICS, Filed by: BlackRock, Inc.
Medium
Report
Form SC 13G CAPRICOR THERAPEUTICS, Filed by: BlackRock, Inc.
11/12
09:19 am
capr
Form EFFECT CAPRICOR THERAPEUTICS,
Medium
Report
Form EFFECT CAPRICOR THERAPEUTICS,
11/8
09:00 am
capr
Form SC 13G/A CAPRICOR THERAPEUTICS, Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC
Low
Report
Form SC 13G/A CAPRICOR THERAPEUTICS, Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC
10/24
02:02 pm
capr
Form SC 13G CAPRICOR THERAPEUTICS, Filed by: BlackRock, Inc.
Low
Report
Form SC 13G CAPRICOR THERAPEUTICS, Filed by: BlackRock, Inc.
10/22
05:12 pm
capr
Form S-3 CAPRICOR THERAPEUTICS,
Medium
Report
Form S-3 CAPRICOR THERAPEUTICS,
10/17
04:16 pm
capr
Form 424B5 CAPRICOR THERAPEUTICS,
Low
Report
Form 424B5 CAPRICOR THERAPEUTICS,
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/29
New Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002
251.2%
7/15 Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy 94.1%
3/24 Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Development 49.2%
3/24 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 21.7%
9/17 Capricor Therapeutics (CAPR) Presents At 21st Annual H.C. Wainwright Global Investment Conference - Slideshow [Seeking Alpha] 19.3%
3/17 Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products Expansion 15.8%
4/30 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 12.0%
9/6 Capricor Therapeutics to Present at Upcoming Conferences 10.3%
10/15 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.1%
12/27 Form SC 13G CAPRICOR THERAPEUTICS, Filed by: ARMISTICE CAPITAL, LLC 9.5%
7/15 Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy 94.1%
3/24 Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Development 49.2%
3/24 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 21.7%
9/17 Capricor Therapeutics (CAPR) Presents At 21st Annual H.C. Wainwright Global Investment Conference - Slideshow [Seeking Alpha] 19.3%
3/17 Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products Expansion 15.8%
4/30 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 12.0%
9/6 Capricor Therapeutics to Present at Upcoming Conferences 10.3%
10/15 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.1%
12/27 Form SC 13G CAPRICOR THERAPEUTICS, Filed by: ARMISTICE CAPITAL, LLC 9.5%
TOP News Decliners
4/3
Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy
-37.5%
7/15 Capricor Therapeutics Inc (NASDAQ: CAPR) had its price target raised by analysts at HC Wainwright from $3.50 to $12.40. They now have a "buy" rating on the stock. -22.1%
7/25 Capricor Therapeutics Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in Duchenne Muscular Dystrophy -16.6%
12/13 Form S-1/A CAPRICOR THERAPEUTICS, -16.0%
10/7 Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months -15.9%
7/22 Form 8-K CAPRICOR THERAPEUTICS, For: Jul 22 -13.0%
11/7 Q3/2019 9/30/2019 EPS -0.430 ZacksConsensus -0.700 ActVsEst 0.270 - Beat -12.4%
12/13 Form S-1/A CAPRICOR THERAPEUTICS, -11.9%
7/16 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.9%
7/17 Form S-3/A CAPRICOR THERAPEUTICS, -10.7%
7/15 Capricor Therapeutics Inc (NASDAQ: CAPR) had its price target raised by analysts at HC Wainwright from $3.50 to $12.40. They now have a "buy" rating on the stock. -22.1%
7/25 Capricor Therapeutics Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in Duchenne Muscular Dystrophy -16.6%
12/13 Form S-1/A CAPRICOR THERAPEUTICS, -16.0%
10/7 Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months -15.9%
7/22 Form 8-K CAPRICOR THERAPEUTICS, For: Jul 22 -13.0%
11/7 Q3/2019 9/30/2019 EPS -0.430 ZacksConsensus -0.700 ActVsEst 0.270 - Beat -12.4%
12/13 Form S-1/A CAPRICOR THERAPEUTICS, -11.9%
7/16 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.9%
7/17 Form S-3/A CAPRICOR THERAPEUTICS, -10.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: